top of page

EnLiSense in the News

Advancing Care with Innovative Sweat Sensor Technology with Leading Clinicians

EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration with top-tier medical institutions to further the management of Chronic Diseases

Funding Surge Empowers NextGen Sensors for Breakthrough in Real-Time Biomarker Management

EnLiSense CCM Receives Funding from Crohn's & Colitis Foundation To Develop Its Real-Time Inflammation Monitor Using Sweat Sensors For Tracking And Monitoring IBD Disease Activity In Patients

Placeholder Image

Clinical Data from UChicago Supports Novel Continuous Calprotectin Monitoring Wearable for IBD Management

EnLiSense's IBD Aware device offers a pioneering solution for managing inflammatory bowel disease by continuously monitoring calprotectin levels non-invasively through innovative passive-perspiration sensor technology.

Placeholder Image

Mount Sinai and EnLiSense: Pioneering Real-Time Biomarker Monitoring through Groundbreaking Studies

EnLiSense’s device offers the first groundbreaking solution for continuous, non-invasive monitoring of inflammatory bowel disease through innovative sweat-sensing technology.

Placeholder Image

Sweat Monitoring: A New Frontier in Chronic Disease Management

Revolutionizing Inflammatory Bowel Disease Management with Cutting-Edge Wearable Technology: A Leap Towards Real-Time, Non-Invasive Monitoring and Insights Through Advanced Sweat Analysis

Learn more about EnLiSense

EnLiSense stands at the forefront of medical innovation, spearheading the development of advanced sweat sensor technology for real-time, non-invasive monitoring. Their offerings include both a first-of-its-kind device and an advanced data and AI platform, blending cutting-edge hardware with sophisticated analytics. Their flagship products, IBD Aware and Corti, are not just wearables; they are gateways to a new era in personalized healthcare. These devices cater to a wide range of use cases, profoundly resonating with both clinicians and patients. They facilitate proactive chronic disease management in conditions like inflammatory bowel disease (IBD) and stress-related disorders, offering clinicians and patients unprecedented insights into both physiological and disease states for treatment timing and effectiveness, symptom management, and dietary and lifestyle adjustments – aspects previously inaccessible in real-time. The technology is validated to continuously monitor a comprehensive range of biomarkers including Calprotectin, CRP, TNF-Alpha, IL-6, Cortisol, Melatonin, Glucose, and many others, transforming how healthcare professionals and patients approach treatment and management.

 

The journey of EnLiSense is characterized by a relentless pursuit of elevating the standard of care through continuous innovation. Their solutions are designed not only to meet current healthcare challenges but also to anticipate future needs. EnLiSense continues to expand research and development efforts into new biomarkers and disease applications, broadening the scope of the technology platform to encompass a wider spectrum of chronic conditions. This expansion is underpinned by a commitment to cost-effective, precision medicine, ensuring that each advancement brings us closer to a future where healthcare is more personalized, proactive, and patient-centered.

bottom of page